XML 43 R28.htm IDEA: XBRL DOCUMENT
v3.24.3

REVENUE (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2024
Revenue from Contract with Customer [Abstract] |
Schedule of Revenue | Total revenues during the three and nine months ended September 30, 2024 and 2023 were as follows (in thousands):
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2024 |  | 2023 |  | 2024 |  | 2023
Product sales, net: |  |  |  |  |  |  |
IBSRELA | $ | 40,638 |  |  | $ | 22,285 |  |  | $ | 104,444 |  |  | $ | 51,949 |
XPHOZAH | 51,452 |  |  | — |  |  | 103,749 |  |  | — |
Total product sales, net | 92,090 |  |  | 22,285 |  |  | 208,193 |  |  | 51,949 |
Product supply revenue | 5,322 |  |  | 2,092 |  |  | 7,461 |  |  | 5,354 |
Licensing revenue | 20 |  |  | 32,014 |  |  | 56 |  |  | 32,790 |
Non-cash royalty revenue related to the sale of future royalties | 809 |  |  | — |  |  | 1,776 |  |  | — |
Total revenues | $ | 98,241 |  |  | $ | 56,391 |  |  | $ | 217,486 |  |  | $ | 90,093 |
Schedule of Revenue from Customers as a Percentage of Total Product Revenue, Net | Revenue from customers who contributed greater than 10% of our total gross product revenue during the three and nine months ended September 30, 2024 and 2023 was as follows (as a percentage of total gross product revenue):
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2024 |  | 2023 |  | 2024 |  | 2023
BioRidge Pharma, LLC | 53.4 | % |  | 19.5 | % |  | 49.3 | % |  | 19.2 | %
AmerisourceBergen Drug Corporation | 14.0 | % |  | 21.2 | % |  | 15.1 | % |  | 21.3 | %
Cardinal Health | 12.6 | % |  | 22.2 | % |  | 13.8 | % |  | 22.3 | %
McKesson Corporation | 13.2 | % |  | 18.4 | % |  | 13.2 | % |  | 19.0 | %
Schedule of Chargebacks, Discounts and Reserve Balances | The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):
| Discounts and Chargebacks |  | Rebates, Wholesaler and GPO Fees |  | Copay and Returns |  | Total
Balance as of December 31, 2023 | $ | 478 |  |  | $ | 4,234 |  |  | $ | 3,916 |  |  | $ | 8,628 |
Provisions | 10,074 |  |  | 43,398 |  |  | 20,390 |  |  | 73,862 |
Credits/payments | (8,974) |  |  | (33,925) |  |  | (16,271) |  |  | (59,170) |
Balance as of September 30, 2024 | $ | 1,578 |  |  | $ | 13,707 |  |  | $ | 8,035 |  |  | $ | 23,320 |

X
- Definition Schedule Of Gross To Net Sales Accruals + References No definition available. + Details
Name: | ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock
Namespace Prefix: | ardx_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-16 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-21 + Details
Name: | us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration